Name: Royalty Pharma plc - Ordinary Shares - Class A (RPRX) Earnings, Actual EPS, EPS Estimates & Results
Creator: Stocktwits

SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Space Exploration Technologies Corp. (SpaceX) designs, manufactures, and launches advanced rockets and spacecraft, including the fully reusable Starship and Super Heavy rocket system, targeting missions to Earth orbit, the Moon, Mars, and beyond. The company is based in Hawthorne, CA and has subsidiaries in Luxembourg and the United States. The company operates Starlink, a low-Earth orbit satellite constellation that delivers high-speed broadband internet worldwide. SpaceX is dedicated to advancing space technology with the goal of enabling human life on other planets. The company was founded in 2002 by Elon Reeve Musk, Kimbal Musk, Michael Kives. Elon Reeve Musk has been the CEO since 2002.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SpaceX is currently trending due to intense volatility following its first quarterly earnings report as a public company, which featured strong revenue growth alongside heavy AI infrastructure spending. Community sentiment is deeply polarized as investors weigh long-term growth potential against concerns over imminent insider share lock-up expirations and the massive cash burn required for Starship and AI projects.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD shares are facing significant selling pressure as investors react to a surge in capital expenditures, despite the company delivering a strong earnings beat and raising guidance. The community is sharply divided, with bulls pointing to robust data center growth and multi-year AI tailwinds, while bears argue the stock's high valuation is unsustainable following its recent run-up.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is capturing significant market attention following an exclusive AI satellite computing partnership with SpaceX, while investors closely monitor the broader rotation from AMD into NVIDIA ahead of earnings. Community discussion remains polarized, with many traders viewing NVIDIA as the primary beneficiary of accelerating AI infrastructure demand, even as some express frustration over persistent short-term price volatility.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is trending as investors focus on its strong growth trajectory and upcoming earnings after a recent streak of beating expectations. While community sentiment remains divided between short-term traders watching volatility and long-term believers citing the company's AI-powered partnerships and expanding free cash flow, many are actively positioning themselves around key support levels ahead of the next financial update.

Digital Turbine, Inc. is a mobile growth platform that offers solutions for advertisers, publishers, carriers, and device original equipment manufacturers (OEMs). The firm operates through the On Device Solutions (ODS) and App Growth Platform (AGP) segments. The ODS segment generates revenue from the delivery of mobile application media or content to end users with solutions for all participants in the mobile application ecosystem that want to connect with end users and consumers who hold the device. This includes mobile carriers and device OEMs that participate in the app economy, app publishers and developers, and brands and advertising agencies. The AGP segment provides platforms that allow mobile app publishers and developers to monetize their monthly active users via display, native, and video advertising. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

Digital Turbine is trending as investors rally behind a strengthened turnaround narrative, fueled by rising revenue guidance and increased institutional interest ahead of upcoming earnings. The community is actively discussing the stock's potential for a broader re-rating, pointing to successful AI integration and a more efficient advertising flywheel as key drivers for recent upward momentum.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

Kratos Defense is trending as investors react to a significant influx of new government funding and contract awards for its hypersonic and autonomous systems. Despite recent price volatility, the community is debating whether the stock's current valuation represents a deep value buying opportunity driven by a long-term defense spending super-cycle.

Upstart Holdings, Inc. engages in the provision of a cloud-based artificial intelligence lending platform. It operates through the following segments: Personal Lending, Auto Lending, and Other. The Personal Lending segment focuses on unsecured personal loans and small dollar loans. The Auto Lending segment is involved in auto refinance and auto retail loans. The Other segment refers to HELOCs and other. The company was founded by David Joseph Girouard, Anna Mongayt Counselman, and Paul Gu in December 2013 and is headquartered in San Mateo, CA.

Upstart Holdings Inc

Upstart Holdings Inc. is seeing intense community discussion surrounding its recent earnings beat, with investors divided between high-conviction bulls anticipating a potential short squeeze and critics citing ongoing volatility and macro pressures. The conversation is heavily focused on the company's return to GAAP profitability and improved contribution margins as key catalysts for a potential reversal.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include Core, Cognitive Adjacencies, and Network Software and Services. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as investors react to a standout quarterly earnings report that crushed revenue and profit expectations, signaling strong, sustained demand for its AI-focused networking infrastructure. While some traders are locking in profits following the stock's significant after-hours jump, the broader community remains bullish on its long-term growth as a key beneficiary of hyperscaler AI buildouts.

AT&T, Inc. is a holding company, which engages in the provision of telecommunications and technology services. It operates through the Communications and Latin America segments. The Communications segment offers wireless, wireline telecom, and broadband services to businesses and consumers located in the US and businesses globally. The Latin America segment provides wireless services and equipment in Mexico. The company was founded in 1983 and is headquartered in Dallas, TX.

AT&T, Inc.

AT&T Inc

AT&T shares are under intense downward pressure as investors weigh rumors of SpaceX's Starlink potentially encroaching on the broadband and mobile markets. While the community is actively debating the viability of satellite competition versus the reliability of AT&T's fiber infrastructure, many investors are focused on the stock's significant dividend yield and potential value at these multi-year lows.

TransMedics Group, Inc. operates as a commercial stage medical technology company. The firm engages in the development and commercialization of organ care system platform. It focuses on the preservation of human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation. The company was founded by Waleed H. Hassanein in August 1998 and is headquartered in Andover, MA.

Transmedics Group Inc

Transmedics Group is facing significant downward pressure as the market reacts to broader macroeconomic concerns, specifically rising oil prices and geopolitical tensions affecting its logistics operations. Despite strong underlying revenue growth and a high-conviction long-term thesis from the investor community regarding its organ transplant infrastructure, the stock's volatility and reliance on flight data have triggered intense debate among shareholders over whether current valuation levels represent a strategic buying opportunity or a deeper correction phase.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Gear Up for Royalty Pharma (RPRX) Q2 Earnings: Wall Street Estimates for Key Metrics

Beyond analysts' top-and-bottom-line estimates for Royalty Pharma (RPRX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2026.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Will Iovance Biotherapeutics (IOVA) Report Negative Q2 Earnings? What You Should Know

Iovance Biotherapeutics (IOVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Royalty Pharma (RPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Why Royalty Pharma (RPRX) Could Beat Earnings Estimates Again

Royalty Pharma (RPRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Are You Looking for a Top Momentum Pick? Why Royalty Pharma (RPRX) is a Great Choice

Does Royalty Pharma (RPRX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Royalty Pharma PLC (RPRX) Hits Fresh High: Is There Still Room to Run?

Royalty Pharma (RPRX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

RPRX or ACAD: Which Is the Better Value Stock Right Now?

RPRX vs. ACAD: Which Stock Is the Better Value Option?

$RPRX Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.53 down -3.64% YoY
• Reported revenue of $631M up 11.04% YoY
• Royalty Pharma expects 2026 Portfolio Receipts to be between $3.33B and $3.45B, an increase from previous guidance, representing expected Royalty Receipts growth of 4% to 8%.

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Royalty Pharma plc - Ordinary Shares - Class A

Why Is TEVA Stock Rising Pre-Market Today?

Equity

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.27	--	--	N/A
Q1 '26	$1.10	$1.30	17.31%	BEAT
Q4 '25	$1.29	$1.47	14.02%	BEAT
Q3 '25	$0.99	$1.17	18.08%	BEAT
Q2 '25	$1.03	$1.14	10.53%	BEAT

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q2 '26

Historical Earnings